Zura Bio (NASDAQ:ZURA) Given New $10.00 Price Target at Chardan Capital

Zura Bio (NASDAQ:ZURA) had its price objective lowered by Chardan Capital from $12.00 to $10.00 in a report published on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages have also recently issued reports on ZURA. HC Wainwright reiterated a “neutral” rating and issued a $5.00 price objective on shares of Zura Bio in a research note on Tuesday, December 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Zura Bio has a consensus rating of “Buy” and a consensus target price of $15.00.

Zura Bio Stock Down 10.4 %

Shares of ZURA opened at $1.34 on Wednesday. Zura Bio has a fifty-two week low of $1.07 and a fifty-two week high of $6.35. The firm’s 50 day moving average price is $1.48 and its 200 day moving average price is $2.76.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. The company had revenue of $0.00 million for the quarter. On average, equities research analysts forecast that Zura Bio will post -0.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. boosted its stake in Zura Bio by 51.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 291,807 shares of the company’s stock valued at $1,185,000 after acquiring an additional 98,972 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Zura Bio in the 3rd quarter valued at about $71,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Zura Bio during the 3rd quarter worth approximately $46,000. MetLife Investment Management LLC acquired a new position in Zura Bio during the third quarter worth approximately $111,000. Finally, Braidwell LP purchased a new stake in Zura Bio in the third quarter valued at approximately $10,040,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.